ARTICLE | Company News

Biogen Idec, Genmab, GlaxoSmithKline, Roche cancer news

March 29, 2010 7:00 AM UTC

Biogen Idec and Roche's Genentech Inc. unit filed a patent infringement suit against GlaxoSmithKline in the U.S. District Court for the Southern District of California related to cancer drug Arzerra ofatumumab from GSK and Genmab. The plaintiffs are seeking declaratory judgment that Arzerra infringes U.S. Patent No. 7,682,612, which was issued on March 23, covering methods of treating chronic lymphocytic leukemia (CLL) with anti- CD20 antibodies. The patent expires in 2019.

Biogen Idec and Genentech are requesting a jury trial and seeking damages. Last October, FDA granted accelerated approval to Arzerra to treat CLL refractory to fludarabine and alemtuzumab. GSK, which has rights to Arzerra from Genmab, said it is studying the patent but does not believe its claims are valid or enforceable. ...